1. Home
  2. EARN vs CRVS Comparison

EARN vs CRVS Comparison

Compare EARN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • CRVS
  • Stock Information
  • Founded
  • EARN 2012
  • CRVS 2014
  • Country
  • EARN United States
  • CRVS United States
  • Employees
  • EARN N/A
  • CRVS N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • CRVS Health Care
  • Exchange
  • EARN Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • EARN 177.0M
  • CRVS 161.4M
  • IPO Year
  • EARN 2013
  • CRVS 2016
  • Fundamental
  • Price
  • EARN $7.02
  • CRVS $5.72
  • Analyst Decision
  • EARN Hold
  • CRVS Buy
  • Analyst Count
  • EARN 2
  • CRVS 4
  • Target Price
  • EARN $6.00
  • CRVS $10.83
  • AVG Volume (30 Days)
  • EARN 390.1K
  • CRVS 455.4K
  • Earning Date
  • EARN 11-11-2024
  • CRVS 11-05-2024
  • Dividend Yield
  • EARN 13.65%
  • CRVS N/A
  • EPS Growth
  • EARN 102.38
  • CRVS N/A
  • EPS
  • EARN 0.23
  • CRVS N/A
  • Revenue
  • EARN $18,419,000.00
  • CRVS N/A
  • Revenue This Year
  • EARN N/A
  • CRVS N/A
  • Revenue Next Year
  • EARN $51.24
  • CRVS N/A
  • P/E Ratio
  • EARN $30.32
  • CRVS N/A
  • Revenue Growth
  • EARN N/A
  • CRVS N/A
  • 52 Week Low
  • EARN $5.09
  • CRVS $1.05
  • 52 Week High
  • EARN $7.26
  • CRVS $6.15
  • Technical
  • Relative Strength Index (RSI)
  • EARN 57.03
  • CRVS 73.81
  • Support Level
  • EARN $6.92
  • CRVS $5.25
  • Resistance Level
  • EARN $7.09
  • CRVS $5.82
  • Average True Range (ATR)
  • EARN 0.08
  • CRVS 0.43
  • MACD
  • EARN 0.01
  • CRVS 0.08
  • Stochastic Oscillator
  • EARN 78.79
  • CRVS 80.67

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: